Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Temporal and Regional Circular RNA profiling in a Tauopathy Mouse Model: Implications for Tau Pathology and Neurodegeneration

Created on 24 Jun 2026

Authors

Pratico, D., Hossein, M. S.

Abstract

MicroRNAs (miRNA), are non-coding RNA that act as post-transcriptional regulators of gene expression in various organs including the brain where they play an important role in neurodegeneration. Circular RNAs are single-stranded, covalently closed loop RNA molecules recognized as upstream regulators of miRNA. Previous studies have shown that circRNAs are dysregulated in Alzheimer and other neurodegenerative diseases. However, a systematic, age and region specific circRNA atlas in primary tauopathy is lacking. To this end, we performed comprehensive circRNA sequencing of hippocampal and cortical tissues from a model of human tauopathy, hTau mice, at 3, 6, and 12 months of age. We identified circRNA miRNA sponging networks that target and regulate key tau disease associated pathways, including kinases, phosphatases, histone deacetylase, glutamatergic and GABAergic synapse, and microglial efferocytosis. Our study demonstrates an age- and region-specific circRNA landscape in the brain of a model of human tauopathy and identify candidate circRNA miRNA mRNA regulatory axes converging on core tau pathological processes. These findings support the novel hypothesis that specific circRNAs have the potential to be used as biomarkers and therapeutic targets against tau-driven neurodegeneration.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 24 Jun 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement